摘要
目的探讨阿司匹林联合西洛他唑治疗进展性脑梗死的临床疗效及安全性。方法 220例进展性脑梗死患者,随机分为实验组和对照组,每组110例。对照组服用阿司匹林,实验组服用阿司匹林联合西洛他唑。比较两组临床疗效。结果治疗2周后实验组美国国立卫生研究院卒中量表(NIHSS)评分低于对照组,差异具有统计学意义(P<0.05);实验组治疗总有效率为96.4%,明显高于对照组的76.4%(P<0.05);治疗后两组凝血酶时间(TT)、活化部分凝血活酶时间(APTT)及凝血酶原时间(PT)指标均较治疗前有显著改善(P<0.05),但组间比较差异无统计学意义(P>0.05)。结论阿司匹林联合西洛他唑治疗进展性脑梗死效果确切,安全性较高,值得推广使用。
Objective To investigate clinical effect and safety by aspirin combined with cilostazol in the treatment of progressive cerebral infarction. Methods A total of 220 patients with progressive cerebral infarction were randomly divided into experimental group and control group, with 110 cases in each group. The control group received aspirin, and the experimental group received aspirin combined with cilostazol. Clinical effects were compared between the two groups. Results After 2 weeks of treatment, the experimental group had lower National Institutes of Health Stroke Scale（NIHSS） score than the control group, and the difference had statistical significance（P〈0.05）. The experimental group had obviously higher total effective rate as 96.4% than 76.4% of the control group（P〈0.05）. Both groups had much better indexes of thrombin time（TT）, activated partial thromboplastin time（APTT） and prothrombin time（PT） after treatment than those before treatment（P〈0.05）, while there was no statistically significant difference between the two groups（P〉0.05）. Conclusion Combination of aspirin and cilostazol provides precise effect and high safety in treating progressive cerebral infarction, and it is worth promoting and applying.
出处
《中国现代药物应用》
2016年第22期1-2,共2页
Chinese Journal of Modern Drug Application
关键词
进展性脑梗死
阿司匹林
西洛他唑
Progressive cerebral infarction
Aspirin
Cilostazol
